Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01393301 · ClinicalTrials.gov registry record · NA
Integrated Treatment for Smoking Cessation & Anxiety in People With HIV
A NA study, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- NA
- Development phase
- 72
- Enrollment target
NCT01393301: Completed NA study, sponsored by Massachusetts General Hospital.
NCT01393301 is a NA study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 72 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01393301, a NA study, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- NA
- Development phase
- 72 participants
- Enrollment target
Study Summary
During the 1-year formative phase of a study to develop an integrated treatment for quitting smoking for anxiety-vulnerable HIV+ smokers. During this first phase of the study, start-up activities will include piloting the integrated treatment on a small group of individuals (N = up to 12), obtaining expert consultant and participant feedback, and development of the final treatment manual and procedures. The goal during this phase will be to establish feasibility of treatment delivery, participant acceptability, and potential for a treatment effect before conducting a pilot randomized trial of the treatment. During the two-year pilot RCT phase of the above study, we directly develop and test a novel psychosocial/behavioral and pharmacological smoking cessation intervention for HIV+ smokers with interfering psychological distress.
Interventions
- BEHAVIORAL Control
- BEHAVIORAL Integrated cognitive-behavioral therapy for smoking cessation and anxiety
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 72 participants |
| Start Date | 2011-10 |
| Est. Completion | 2015-05 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01393301
The ClinicalTrials.gov registry entry for NCT01393301 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 72 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Control is the first listed.
NCT01393301 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01393301 about?
NCT01393301 is a clinical study titled "Integrated Treatment for Smoking Cessation & Anxiety in People With HIV". During the 1-year formative phase of a study to develop an integrated treatment for quitting smoking for anxiety-vulnerable HIV+ smokers. During this first phase of the study, start-up activities will include piloting the integrated treatment on a small group of individuals (N = up to 12), obtaining...
What is the current status of trial NCT01393301?
This trial is currently completed. It is a NA study. The enrollment target is 72 participants. The study started on 2011-10. Estimated completion is 2015-05.
What interventions are being tested in trial NCT01393301?
The interventions under investigation include: Control (BEHAVIORAL), Integrated cognitive-behavioral therapy for smoking cessation and anxiety (BEHAVIORAL).
Who is sponsoring clinical trial NCT01393301?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.